Article
Oncology
Xueqiong Xun, Qinguang Cao, Pan Hong, Saroj Rai, Yeming Zhou, Ruikang Liu, Huiyong Hu
Summary: This meta-analysis found that the addition of capecitabine to standard adjuvant chemotherapy in early-stage TNBC patients significantly improved disease-free survival and overall survival with manageable adverse events. Lower dosage and higher frequency of capecitabine combined with adjuvant chemotherapy showed better survival outcomes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu
Summary: This study analyzed the cost-effectiveness of neratinib plus capecitabine (N+C) and lapatinib plus capecitabine (L+C) in HER2-positive metastatic breast cancer. The results showed that N+C was dominant in most scenarios, providing an improvement of 0.17 quality-adjusted life-years (QALYs) and reducing costs compared to L+C. The ICER was below the willingness to pay threshold, indicating that N+C is a cost-effective third-line treatment option for HER2-positive metastatic breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jun Cao, Yuee Teng, Huiping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo, Xichun Hu
Summary: This study investigated the efficacy and safety of pyrotinib plus capecitabine in HER2-positive advanced breast cancer patients with primary resistance to trastuzumab. The results showed that this combination therapy can be considered as a treatment option for these patients.
Article
Oncology
M. M. Javle, D-Y Oh, M. Ikeda, W-P Yong, K. Hsu, B. Lindmark, N. McIntyre, C. Firth
Summary: The study assessed the efficacy of varlitinib plus capecitabine in treating recurrent advanced biliary tract cancer. The results showed that varlitinib plus capecitabine did not improve efficacy compared to capecitabine alone, but may provide a PFS benefit in female patients and those with gallbladder cancer.
Article
Medicine, General & Internal
J. Cortes, H. S. Rugo, D. W. Cescon, S-A Im, M. M. Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V Karantza, W. Pan, P. Schmid
Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Summary: The combination of orally administered metronomic capecitabine and pyrotinib in HER2 positive metastatic breast cancer patients shows promising efficacy and improved tolerability.
Review
Chemistry, Medicinal
Giovanna Chila, Vincenzo Guarini, Danilo Galizia, Elena Geuna, Filippo Montemurro
Summary: Neratinib is a valuable therapeutic option for metastatic, HER2-positive breast cancer, particularly in cases of trastuzumab-resistant disease. Although it has shown positive effects on progression-free survival and response duration, it did not confer an overall survival benefit or improvement in quality of life in the NALA trial.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Jusheng An, Xiumin Li, Jing Wang, Lijing Zhu, Ruifang An, Kui Jiang, Yi Huang, Ke Wang, Guiling Li, Chunyan Wang, Jianlin Yuan, Xiaoli Hou, Guiyu Yang, Jing Li, Qingyu Wang, Jun Zhu, Lingying Wu
Summary: This study reports the efficacy and safety of serplulimab combined with nanoparticle albumin-bound paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer. The combination treatment showed durable clinical activity and a manageable safety profile.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Medicine, General & Internal
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice Andre, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O'Shaughnessy
Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Summary: PIK3CA mutations were associated with shorter PFS, while higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C compared with L+C.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Pui Lam Yip, Wai Him Brian Fung, Francis Ann Shing Lee, Chak Fei Lee, Natalie Sean Man Wong, Shing Fung Lee
Summary: This retrospective study reports the real-world effectiveness and safety of modified CAPIRI-P (mCAPIRI-P) regimen in patients with metastatic colorectal cancer. The results show that mCAPIRI-P is a safe and effective first-line treatment for RAS wild-type advanced colorectal cancer, and further research is warranted.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Martina Puglisi, L. Rhoda Molife, Maja J. A. de Jonge, Khurum H. Khan, Leni van Doorn, Martin D. Forster, Montserrat Blanco, Martin Gutierrez, Catherine Franklin, Todd Busman, Jianning Yang, Ferry A. L. M. Eskens
Summary: This Phase I study explored the safety and efficacy of navitoclax and docetaxel in patients with advanced solid tumors. The maximum tolerated dose was determined to be navitoclax 150mg orally once/day in combination with docetaxel. Despite dose-limiting toxicities, there were observed instances of antitumor activity, including four confirmed partial responses.
Article
Oncology
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortes, Jean-Charles Soria, Giuseppe Curigliano
Summary: Recent years have seen a shift in cancer treatment towards therapies tailored to specific molecular aberrations and immunologic markers, rather than solely relying on histology. Several histology-agnostic therapies are now adopted in clinical practice for treating patients, and novel antibody-drug conjugates (ADCs) have shown promise in treating solid tumors. The multihistological expansion of ADCs poses both challenges and opportunities for cancer treatment.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Silvia Gonzalez-Martinez, David Pizarro, Belen Perez-Mies, Tamara Caniego-Casas, Jose Luis Rodriguez-Peralto, Giuseppe Curigliano, Alfonso Cortes, Maria Gion, Javier Cortes, Jose Palacios
Summary: The risk of cutaneous metastasis exists in breast cancer. Nearly half of the patients with cutaneous metastasis exhibit additional molecular alterations. Although there is no specific mutational pattern, these alterations can potentially impact treatment.
Article
Oncology
Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A. Mittendorf, Hope Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice Andre, Giuseppe Curigliano
Summary: Advancements in the treatment of localized triple negative breast cancer (TNBC) are reshaping the landscape of this disease, with the addition of pembrolizumab showing significant improvement in survival. However, there are still questions regarding patient selection, integration with other treatments, and minimizing side effects.
Review
Oncology
Andrea Aran, Laia Garrigos, Giuseppe Curigliano, Javier Cortes, Merce Marti
Summary: The study of TCR repertoire in cancer patients is important for understanding the anti-tumoural response, predicting prognosis, and determining response to immune checkpoint inhibitor therapies. The TCR repertoire is influenced by various factors and can provide valuable insights for modulating immune responses and predicting outcomes.
Article
Oncology
Simona Bruzas, Oleg Gluz, Nadia Harbeck, Peter Schmid, Javier Cortes, Jens Blohmer, Christine Seiberling, Ouafaa Chiari, Hakima Harrach, Beyhan Ataseven, Satyendra Shenoy, Mark H. Dyson, Eugen Traut, Ingo Theuerkauf, Daniel Gebauer, Sherko Kuemmel, Mattea Reinisch
Summary: A significant number of early breast cancer patients experience relapse after neoadjuvant therapy, even if the tumors achieved pathologic complete response (pCR). Gene expression analysis revealed that recurrent tumors had lower expression of estrogen receptor signaling and immune-related expression parameters compared to primary tumors. Interindividual analysis showed that patients with any relapse or distant relapse had lower expression of major histocompatibility complex class II in their primary tumors. Additionally, primary tumors with later distant relapse had higher homologous recombination deficiency. Although these associations did not remain statistically significant after adjusting for false discovery rate, our findings suggest that transcriptomic analysis has potential prognostic value for early breast cancer patients at risk of relapse and should be further investigated.
Article
Medicine, General & Internal
J. Cortes, H. S. Rugo, D. W. Cescon, S-A Im, M. M. Yusof, C. Gallardo, O. Lipatov, C. H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V Karantza, W. Pan, P. Schmid
Summary: The addition of pembrolizumab to chemotherapy significantly improves overall survival in patients with advanced triple-negative breast cancer whose tumors express PD-L1 with a CPS of 10 or more.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Hope S. Rugo, Aditya Bardia, Frederik Marme, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gomez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Article
Oncology
Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song, Patricia Cortazar
Summary: The study aimed to evaluate the outcomes and recurrence risks for patients with HER2-positive early breast cancer who achieved pathological complete response (pCR) after neoadjuvant HER2-targeted therapy plus chemotherapy. The results showed that patients treated with dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings had the highest 4-year event-free survival rates, suggesting that this treatment approach may provide the most benefit for patients with HER2-positive early breast cancer.
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Cristina Saavedra, Maria Gion, Javier Cortes, Antonio Llombart-Cussac
Summary: Despite advancements in precision medicine for breast cancer, more research is needed to improve cure rates for early-stage patients and extend survival with optimal quality of life for those with metastatic disease. Major progress was made last year, thanks to the significant impact of immunotherapy on survival in triple-negative breast cancer and the promising results of antibody-drug conjugates.
Review
Oncology
Maximilian J. Mair, Rupert Bartsch, Emilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortes, Hui K. Gan, Nancy U. Lin, Andrew B. Lassman, Patrick Y. Wen, Michael Weller, Martin van den Bent, Matthias Preusser
Summary: Antibody-drug conjugates (ADCs) have shown efficacy in various cancers, but their activity in the central nervous system (CNS) may be limited by the blood-brain barrier. This review summarizes the available clinical data on ADCs against primary and secondary brain tumors and ongoing trials. It also discusses the physical, biological, and molecular determinants of ADCs' CNS activity and potential strategies to improve drug delivery to brain tumors.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Summary: Capivasertib-fulvestrant therapy significantly improves progression-free survival in patients with hormone receptor-positive advanced breast cancer, particularly those with AKT pathway alterations.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Aditya Bardia, Javier Cortes, Sara A. Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi-Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O'Shaughnessy
Summary: This study aims to evaluate the efficacy and safety of Amcenestrant in combination with Palbociclib as first-line therapy for estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Pre-/postmenopausal women and men with no prior systemic therapy are enrolled and randomized to receive either Amcenestrant plus Palbociclib or Letrozole plus Palbociclib. The primary endpoint is progression-free survival, and the key secondary endpoint is overall survival, along with safety, pharmacokinetics, and quality of life assessments.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)